Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

IF 7.9 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Leonor Matos, Mette van Ramshorst, Volkmar Müller, Elisa Agostinetto, Sabine Linn, Matteo Lambertini, Veronique Dieras, Fanny le Du, Sofia Braga, Carmen Criscitiello, Katarzyna J Jerzak, Gil Morgan, Sara Brucker, Patricia von Kroge, Renate Haidinger, Gema Rodríguez Recio, Eva Schumacher-Wulf, Mario Fontes Sousa, Francesco Schettini, Elena Laakmann
{"title":"Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.","authors":"Leonor Matos, Mette van Ramshorst, Volkmar Müller, Elisa Agostinetto, Sabine Linn, Matteo Lambertini, Veronique Dieras, Fanny le Du, Sofia Braga, Carmen Criscitiello, Katarzyna J Jerzak, Gil Morgan, Sara Brucker, Patricia von Kroge, Renate Haidinger, Gema Rodríguez Recio, Eva Schumacher-Wulf, Mario Fontes Sousa, Francesco Schettini, Elena Laakmann","doi":"10.1016/j.breast.2025.104558","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS.</p><p><strong>Methods: </strong>International cross-sectional online survey for patients and physicians, distributed from May 2023 to February 2024. Patients with BC diagnosis were deemed eligible for patients' survey completion and BC-treating physicians were invited to fill the physicians' questionnaire.</p><p><strong>Results: </strong>A total of 529 physicians from 50 countries (80 % European) responded, mostly medical oncologists (70 %) working in academic hospitals (53 %). Most physicians request BIS (65 %), mainly when extracranial progression occurs, especially for HER2+ and triple negative BC (TNBC). Among physicians never performing BIS (35 %), 91 % would in case of proved clinical benefit. A total of 545 patients from 14 European countries completed the questionnaire. Median age was 50 years, 86 % had metastatic BC, 51 % hormone receptor-positive (HR+)/HER2-negative, 30 % HER2-positive (HER2+) and 19 % TNBC. BM were diagnosed in 11.5 % patients with metastatic BC. 85 % patients would like to undergo BIS, especially younger ones (p = 0.02) and with HR-disease (p = 0.03), despite the uncertain clinical benefit. Notably, 91 % of patients would like to receive information regarding BM, while only 13 % of physicians routinely address the issue.</p><p><strong>Conclusions: </strong>These results underline the willingness of patients to know more about the prospects of BM development, in contrast to the lack of routine discussion of this topic by physicians. Further investigation is warranted to demonstrate the clinical utility of routine BIS.</p>","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104558"},"PeriodicalIF":7.9000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.breast.2025.104558","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS.

Methods: International cross-sectional online survey for patients and physicians, distributed from May 2023 to February 2024. Patients with BC diagnosis were deemed eligible for patients' survey completion and BC-treating physicians were invited to fill the physicians' questionnaire.

Results: A total of 529 physicians from 50 countries (80 % European) responded, mostly medical oncologists (70 %) working in academic hospitals (53 %). Most physicians request BIS (65 %), mainly when extracranial progression occurs, especially for HER2+ and triple negative BC (TNBC). Among physicians never performing BIS (35 %), 91 % would in case of proved clinical benefit. A total of 545 patients from 14 European countries completed the questionnaire. Median age was 50 years, 86 % had metastatic BC, 51 % hormone receptor-positive (HR+)/HER2-negative, 30 % HER2-positive (HER2+) and 19 % TNBC. BM were diagnosed in 11.5 % patients with metastatic BC. 85 % patients would like to undergo BIS, especially younger ones (p = 0.02) and with HR-disease (p = 0.03), despite the uncertain clinical benefit. Notably, 91 % of patients would like to receive information regarding BM, while only 13 % of physicians routinely address the issue.

Conclusions: These results underline the willingness of patients to know more about the prospects of BM development, in contrast to the lack of routine discussion of this topic by physicians. Further investigation is warranted to demonstrate the clinical utility of routine BIS.

转移性乳腺癌的脑成像筛查:患者和医生的观点。
背景:目前不推荐对无神经症状的转移性乳腺癌(BC)患者进行常规脑成像筛查(BIS),因为没有证据表明生存/生活质量得到改善。我们的目的是检查医生和患者对BIS的态度和看法。方法:2023年5月至2024年2月对患者和医生进行国际横断面在线调查。诊断为BC的患者被认为有资格完成患者调查,并邀请治疗BC的医生填写医生问卷。结果:共有来自50个国家的529名医生(80%是欧洲人)参与了调查,其中大部分是在学术医院工作的肿瘤学家(70%)(53%)。大多数医生要求BIS(65%),主要是在发生颅外进展时,特别是HER2+和三阴性BC (TNBC)。在从未实施BIS的医生中(35%),91%的医生会在证明临床获益的情况下进行BIS。共有来自14个欧洲国家的545名患者完成了问卷调查。中位年龄为50岁,86%为转移性BC, 51%为激素受体阳性(HR+)/HER2阴性,30%为HER2阳性(HER2+), 19%为TNBC。11.5%的转移性BC患者被诊断为脑转移。85%的患者愿意接受BIS,尤其是年轻患者(p = 0.02)和患有hr疾病的患者(p = 0.03),尽管临床获益不确定。值得注意的是,91%的患者希望获得有关BM的信息,而只有13%的医生经常解决这个问题。结论:这些结果强调了患者愿意更多地了解BM发展的前景,而不是医生对这一主题缺乏常规讨论。需要进一步的研究来证明常规BIS的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Breast
Breast 医学-妇产科学
CiteScore
8.70
自引率
2.60%
发文量
165
审稿时长
59 days
期刊介绍: The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信